MELBOURNE, Australia and INDIANAPOLIS, May 30, 2022 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on the U.S. and Australian launch and reimbursement status for its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium (68Ga) gozetotide). U.S. Launch Update: Full reimbursement in the U.S. to be effective from July 1.